Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Thursday, September 30, 2021 10:29:28 AM
Compassionate Use Patients = CRITICAL CONDITION...likely days away from dying...and likely going on or on ventilators...
IMO...in spite of the condition and even death post due to ORGAN FAILURE FROM COVID ravaging their system... Brilacidin's effects against COVID will be evident...i.e eliminating the virus in the patient even patients on the cusp of death...eliminating the additional strain of the virus while the organs attempt to heal themselves...
It would be logical to assume that the younger the Critical Condition patient the more chance of survival...but much will be learned.
IMO...based upon PR's and RBL...we will find via the several (or more) Compassionate Use cases the board via FB has apparently learned about...BRILACIDIN demonstrates POSITIVE SYSTEMIC EFFECTS...even IF a patient expires.
ON THE OTHER HAND... the Brilacidin concluded CLINICAL TRIAL is populated with ONLY "moderate to severe"...likely NOT LIKELY WITH PATIENTS WHOSE ORGANS ARE LIKELY DAMAGED FROM COVID..."beyond no return" experienced by CRITICALLY ILL Patients...according to the protocol they were not in critical condition...and therefore the healthier, likely less organ impairment, and more opportunity for Brilacidin to do its wonders is afforded...
IMO look for great results shortly!...and
Know what your own!
GLTAL (Longs)
PS. Effectively eliminating the VIRUS while assisting the body opportunity to repair organs...is what a Therapeutic is supposed to do... It's NOT a Heart, Liver, Lung, or Kidney medicine, but it can aid attempts by the body by eliminating the Virus and its deleterious effects on those organs...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM